New
HealthMore in Health→
Oral GLP-1 Pill Safiglipron Matches Dapagliflozin on HbA1c in Phase 3 Diabetes Trial
Key Takeaways
- A phase 3 trial published in Nature Medicine on 5 October 2026 compared oral safiglipron, a small-molecule GLP-1 receptor agonist, with dapagliflozin.
- The published summary reports safiglipron was non-inferior to dapagliflozin for HbA1c reduction at all doses tested and superior at one dose level.
- The trial was randomized, double-blind and active-comparator-controlled rather than placebo-controlled.
- The summary does not disclose patient numbers, effect sizes, weight data or adverse-event rates; a truncated phrase on superiority leaves one figure unconfirmed.
DE
DT Editorial Team··via nature.com